The largest database of trusted experimental protocols

Lymph Node Excision

Lymph Node Excision is a surgical procedure involving the removal of one or more lymph nodes, typically from the neck, armpit, or groin area.
This procedure is commonly performed to diagnose or treat conditions affecting the lymphatic system, such as cancer, infection, or inflammation.
The excised lymph nodes are then analyzed to determine the underlying cause and guide further treatment.
Lymph Node Excision is an important diagnostic and therapeutic tool in the management of various medical conditions, and understanding the optimal protocols and techniques for this procedure can enhance reproducibility, accuracy, and overall research outcomes.

Most cited protocols related to «Lymph Node Excision»

The Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) is a national disease registry accruing men with biopsy-proven prostate adenocarcinoma, recruited from 40 urology practices, primarily community-based, across the United States. Informed consent is obtained from each patient under institutional review board supervision. Patients are treated according to their physicians’ usual practices, and are followed until time of death or withdrawal from the study. Additional details have been reported previously.13 (link), 14 (link) Eligibility for inclusion in the study was limited to men with prostate cancer diagnosed since 1992 who underwent prostatectomy as primary treatment and had at least six months of followup recorded in the registry. Those with clinically advanced disease (>cT3aN0M0) pre-operatively were ineligible, as were those had received neoadjuvant or adjuvant hormonal and/or radiation.
Detailed reporting of staging variables (ECE, SVI, SM) is variable among pathology reports accessioned to CaPSURE. In the main analysis, ECE, SVI, or SM reported as “unable to assess” were assumed to be negative; in a sensitivity analysis, cases without complete data for all variables were dropped. To examine whether cases with missing pathologic data (ECE, SVI, SM) differed from cases with complete data, we compared these groups with respect to their distributions of the original preoperative CAPRA score using a Wilcoxon rank-sum statistic. In all cases, patients with no lymphadenectomy performed were assumed to have negative LNI. Patients missing pathologic Gleason score and/or preoperative PSA were excluded.
The definition of biochemical recurrence was either 2 consecutive PSA values over 0.2 ng/ml15 (link) or any secondary treatment at least six months following surgery (treatment within six months was assumed to be adjuvant). Men not experiencing recurrence—including those dying of other causes—were censored at date of the last available PSA.
Publication 2011
Adenocarcinoma Biopsy Eligibility Determination Ethics Committees, Research Goat Hypersensitivity Lymph Node Excision Neoadjuvant Therapy Operative Surgical Procedures Patients Pharmaceutical Adjuvants Physicians Prostate Cancer Prostatectomy Prostatic Diseases Radiotherapy Recurrence Supervision
Over the 6‑month period covering April 2010 to September 2010, all patients admitted to one of our patient wards at the Division of General Surgery, Department of Surgery, Medical University of Vienna were included in this study.
The Division of General Surgery in our university hospital consists of the following teams and specializations: colorectal surgery, hepatobiliary surgery, endocrine surgery, upper gastrointestinal (GI) surgery (esophageal and stomach surgery), bariatric surgery, breast surgery, and pancreatic surgery.
The patient data were extracted by reviewing all discharge letters from that period taken from the digital archives.
Overall, 517 patients were admitted over this period, some repeatedly, leading to a total of 817 admissions. These 517 patients underwent 463 operations. The complications of these operations were then rated according to the Clavien-Dindo classification (Table 1). For easier use, the suffix “d” for permanent disability was not drawn upon.

Clavien-Dindo classification

GradeDefinition
Grade IAny deviation from the normal postoperative course without the need for pharmacological treatment, or surgical, endoscopic, and radiological interventions.Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, diuretics and electrolytes, and physiotherapy. This grade also includes wound infections opened at the bedside
Grade IIRequiring pharmacological treatment with drugs other than such allowed for grade I complications.Blood transfusions and total parenteral nutrition are also included
Grade IIIRequiring surgical, endoscopic, or radiological intervention
Grade IIIaIntervention not under general anesthesia
Grade IIIbIntervention under general anesthesia
Grade IVLife-threatening complication (including central nervous system complications) requiring IC/ICU management
Grade IVaSingle organ dysfunction (including dialysis)
Grade IVbMultiorgan dysfunction
Grade VDeath of a patient

According to Dindo et al. [6 (link)]

IC intermediate care, ICU intensive care unit

The operations were sorted according to the complexity ranking (eight groups) in the accounting system of the Austrian Chamber of Physicians (Table 2; [8 ]).

Operation groups (complexity according to the Austrian Chamber of Physicians)

Operation groupExamples
IAbscess incisions, secondary sutures, proctoscopy, skin biopsy
IIExcisions of atheromas, fibromas, lipomas, incisions of anal abscesses
IIIToe amputation, small lymph node extirpation, thoracic drainage, colonoscopy
IVTracheotomy, appendectomy, hernia operation, colostomy, gastrostomy, ERCP
VGastroenterostomy, interventions for recurrent hernia, Cimino fistula, radical varicose vein stripping
VIStrumectomy, cholecystectomy, splenectomy, hemicolectomy, reduction mammoplasty
VIIPartial pancreatectomy, subtotal colectomy, subsegmental and large liver resections
VIIIEsophageal resection, open surgery of aortic aneurysms, organ transplantation
Full text: Click here
Publication 2018
Amputation Antiemetics Antipyretics Anus Aortic Aneurysm Appendectomy Atheroma Bariatric Surgery Blood Transfusion Central Nervous System Cholecystectomy Colectomy Colostomy Dialysis Disabled Persons Diuretics Drainage Electrolytes Endocrine Surgical Procedures Fibroma Fingers Fistula Gastrointestinal Surgical Procedure Gastrostomy Hemicolectomy Hepatectomy Hernia Intensive Care Lipoma Lymph Node Excision Operative Surgical Procedures Organ Transplantation Pancreas Pancreatectomy Parenteral Nutrition, Total Patient Discharge Patients Pharmaceutical Preparations Pharmacotherapy Physicians Proctoscopy Skin Splenectomy Stomach Surgical Endoscopy Surgical Wound Sutures Therapeutics Therapy, Physical Thoracic Surgical Procedures Treatment Protocols Upper Gastrointestinal Tract Varices Wound Infection X-Rays, Diagnostic
Using an existing Institutional Review Board (IRB)-approved database, we reviewed the results of all patients who underwent primary surgery with SLN mapping for endometrial cancer from September 2005 to December 2011 at Memorial Sloan-Kettering Cancer Center (MSKCC). Surgical staging involved total hysterectomy, bilateral salpingo-oophorectomy, and SLN mapping, with additional full pelvic and/or paraaortic lymph node dissection based on attending discretion. All modalities of surgical assessment were included.
Lymphatic mapping was performed in all cases by injecting 1mL of blue dye into the cervical stroma at superficial and deep levels at the 3 and 9 o’clock positions for a total of 4 mL. Blue nodes were dissected and sent as SLNs for pathologic review, as previously described.2 (link) Any suspicious or grossly enlarged nodes, per surgeon’s assessment, were removed and sent separately as non-SLNs.
Clinical patient characteristics, pathologic results, and operative reports were evaluated using the electronic medical record. Adjuvant chemotherapy and/or radiation was recommended and given as per physician discretion.
Publication 2013
Chemotherapy, Adjuvant Endometrial Carcinoma Ethics Committees, Research Female Castrations Hysterectomy Lymph Node Excision Malignant Neoplasms Neck Operative Surgical Procedures Patients Pelvis Physicians Radiotherapy Surgeons
This is a retrospective study using the National Cancer Institute Surveillance, Epidemiology, and End Results Program, a publicly available and deidentified population-based tumor registry covering approximately 28% of the U.S. population.9 The data entry to this database is performed by registered staff personnel with rigorous quality control.10 The institutional review board at the University of Southern California exempted this study as a result of the use of publicly available, deidentified data.
The data set extraction was performed by using SEER*Stat 8.3.2 to use the SEER18 cases for malignancies in “Corpus Uteri/Uterus NOS.” Within the extracted cases, women aged younger than 50 years with stage I endometrioid endometrial cancer diagnosed between 1983 and 2013 who had ovarian conservation at hysterectomy were included in the study cohort. This age cutoff was chosen based on mean age of spontaneous menopause in the North American population.11 (link) Sarcoma or metastatic tumors to the uterus from another origin, no or unknown hysterectomy status, neoadjuvant radiotherapy, no or unknown ovarian conservation status, stage II–IV or unknown stage, nonendometrioid histology types, and age 50 years or older were excluded from the analysis.
To identify the subsequent ovarian cancers, an ovarian cancer data set was generated from the section for malignancies in “Ovary” in the same study period. Then, the ovarian cancer data set was linked with the endometrial cancer data set by sorting according to the unique database identification number. The same study identification numbers between the two data sets were considered secondary primary cancer, as described and validated previously.12 (link)The chronologic time sequence of the endometrial cancer diagnosis date and the ovarian cancer diagnosis date were examined among the secondary primary cancer cases. Then, 1) women in whom primary ovarian cancer was diagnosed before the date of endometrial cancer and 2) women with synchronous endometrial and ovarian cancers were excluded from the study. Ovarian cancers diagnosed 6 months or later after an endometrial cancer diagnosis were considered subsequent ovarian cancers. The cutoff value of a 6-month time interval between the two cancer diagnoses is based on the rationale that endometrial cancer is commonly diagnosed by endometrial sampling before hysterectomy and ovarian cancer is generally diagnosed at the time of subsequent hysterectomy. Nearly 90% of women with endometrial cancer undergo hysterectomy within 4 months of diagnosis.13 (link)-15 (link)Among the eligible cases for analysis, patient demographics, tumor information, treatment patterns, and survival outcome were ascertained from the database. Patient demographics included age, year and month of diagnosis, ethnicity, marital status, and registration area. Tumor information included cancer stage, histologic subtype, tumor grade, and tumor size. For treatment patterns, use of hysterectomy, oophorectomy, pelvic lymphadenectomy, and postoperative radiotherapy was abstracted. For survival, cause-specific survival and overall survival were examined.
Recorded cancer stage was reclassified using the American Joint Committee on Cancer 7th surgical–pathologic staging classification schema.16 The International Classification of Diseases for Oncology, 3rd Revision codes for disease site histology validation and World Health Organization histologic classification were used for grouping histologic subtypes as reported previously.5 (link) Women with surgical codes for hysterectomy without oophorectomy were classified as having undergone ovarian conservation as described previously.5 (link),7 (link),8 (link)Endometrial cancer-specific survival was defined as the time interval between the endometrial cancer diagnosis and the death from endometrial cancer. Overall survival was defined as the time interval between the endometrial cancer diagnosis and the death from any reason (all-cause). This definition was also applied to the ovarian cancer cases. Cause of death in this database is linked with the National Death Index and the state mortality records.17 The primary study endpoint was the cumulative incidence of subsequent ovarian cancer after ovarian conservation in women aged younger than 50 years with stage I endometrioid endometrial cancer. The secondary study objective was to examine tumor characteristics and outcome of subsequent ovarian cancer. Kaplan-Meier method was used to construct cumulative risk curves for subsequent ovarian cancer18 ; and statistical significance between the curves was examined with a log-rank test for univariable analysis. In addition, a Cox proportional hazard regression model was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for subsequent ovarian cancer risk.19 Based on our recent study,5 (link) we estimated eligible cases for this study to be approximately 1,300–1,500. We also assumed the subsequent ovarian cancer risk to be less than 1–2% after ovarian conservation at the time of hysterectomy.20 (link) Thus, we did not perform multivariable analysis because it may result in over-adjustment. All hypotheses were two-tailed, and P<.05 was considered statistically significant. SPSS 24.0 was used for the analysis. The Strengthening the Reporting of Observational Studies in Epidemiology guidelines were used to outline the performance of this observational study.21 (link)
Publication 2017
Diagnosis Endometrial Carcinoma Endometrium Ethics Committees, Research Ethnicity Hysterectomy Joints Lymph Node Excision Malignant Neoplasms Menopause Muscle Rigidity Neoadjuvant Radiotherapy Neoplasms North American People Operative Surgical Procedures Ovarian Cancer Ovariectomy Ovary Patients Pelvis Radiotherapy Sarcoma Second Primary Cancers Uterine Neoplasms Uterus Woman Youth

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2011
Aortopulmonary Septal Defect Arm, Upper Bronchi Bronchus, Primary Cryoultramicrotomy Dissection Eligibility Determination Esophagus Ethics Committees, Research Ligaments Lung Lung Neoplasms Lymph Node Dissection Lymph Node Excision Lymphoid Tissue Malignant Neoplasms Mediastinal Neoplasms Mediastinoscopy Mediastinum Mucocutaneous Lymph Node Syndrome Muscle Rigidity Neoplasms Nervousness Nodes, Lymph Non-Small Cell Lung Carcinoma Patients Pericardium Stem, Plant Surgeons Teaching Thoracic Surgery, Video-Assisted Thoracotomy Trachea Trunks, Brachiocephalic Vena Cavas, Superior

Most recents protocols related to «Lymph Node Excision»

We retrieved patients from the SEER database (2006–2017). Patients between 2004 and 2005 were not included in the study because of the missing chemotherapy data in the SEER database. The inclusion criteria were as follows: (1) positive histology; (2) underwent radical surgery; (3) definite tumor stage (T-category) and nodal stage (N-category), according to the 8th edition of the American Joint Committee on Cancer (AJCC) criteria; (4) first primary tumor; (5) at least one regional lymph node dissection based on pathologic evidence; (6) treatment with/without preoperative radiotherapy and/or chemotherapy; and (7) no distant metastasis. The exclusion criteria were: (1) under 18 years old; (2) unavailable follow-up data; (3) unknown cause of death. We retrieved baseline characteristics, including the year of diagnosis, race, age, sex, histology, grade, marital status, T-category and N-category. The data from all subjects from the SEER database was obtained legally.
Full text: Click here
Publication 2023
Diagnosis Joints Lymph Node Excision Malignant Neoplasms Neoplasm Metastasis Neoplasms Operative Surgical Procedures Patients Pharmacotherapy Radiotherapy
All patients received PD-1/PD-L1 immune checkpoint inhibitors combined with platinum-based doublet chemotherapy as neoadjuvant chemoimmunotherapy. Chemoimmunotherapy drugs were given on the first day of each treatment cycle (21 days per cycle). A standard staging evaluation was performed before and after neoadjuvant chemoimmunotherapy, including a computed tomography (CT) scan (11 (link)); 18-F-fluorodeoxyglucose positron emission tomography/CT scan; magnetic resonance imaging or CT for the brain; and a bronchoscopy examination. All patients received 18-F-fluorodeoxyglucose positron emission tomography/CT scan to assess the presence of mediastinal involvement before and after neoadjuvant chemoimmunotherapy. Surgery was planned 3–7 weeks after the first day of the last treatment cycle. If there were progressive M1 or N3 metastasis after neoadjuvant chemoimmunotherapy, patients would continue medical therapy and be excluded from this study. The type of resection for the primary tumor was determined according to standard institutional procedures, including lobectomy, bronchial or vascular sleeve lobectomy, bilobectomy, and pneumonectomy. Systematic lymphadenectomy was performed in every patient. Decisions of conversion to thoracotomy were made by surgeons during operation whenever they felt necessary. Pathological responses and yield pathologic stage (yp-stage) were determined by the Department of Pathology according to resected samples.
Patients were divided into the VATS or RATS groups according to the initial surgery approach. Surgery approach was determined by patients’ will. All surgeries were performed by surgeons with extensive experience. VATS was performed in a two-port or three-port approach liberally. RATS was performed using the Da Vinci Xi surgery system (Intuitive Surgical, Inc., Mountain View, CA, USA), using the three-arm method. Patients without viable tumor cells in resected lymph nodes and primary lung cancer were defined as pCR, while less than 10% of viable tumor cells were defined as MPR, and more than 10% were defined as an incomplete pathological response (IPR) (12 (link)).
Full text: Click here
Publication 2023
Antineoplastic Combined Chemotherapy Protocols Blood Vessel Brain Bronchi Bronchoscopy CD274 protein, human Cells F18, Fluorodeoxyglucose Feelings Immune Checkpoint Inhibitors Lung Cancer Lymph Node Excision Mediastinum Neoadjuvant Therapy Neoplasm Metastasis Neoplasms Operative Surgical Procedures Patients Pharmaceutical Preparations Platinum Pneumonectomy Radionuclide Imaging Rattus norvegicus Scan, CT PET Surgeons Therapeutics Thoracic Surgery, Video-Assisted Thoracotomy X-Ray Computed Tomography
1. Age of 18–75 years
2. Preoperative radiographic assessment including pelvic magnetic resonance imaging or abdominal computerized tomography (CT) is performed to determine tumor is confined to uterus including cervical involvement. Preoperative histology indicates EEC.
3. A history of surgery with curative intent, including total abdominal or laparoscopic hysterectomy, bilateral salpingectomy with or without oophorectomy, pelvic lymphadenectomy or sentinel lymph node mapping and dissection, with or without para-aortic lymphadenectomy
4. Primary histologically confirmed EEC, with one of the following combinations:
1. Eastern Cooperative Oncology Group performance status of 0 or 1
2. Adequate systemic organ function, as follows:
3. Signed, written informed consent
Publication 2023
Abdomen Aorta Dissection Hysterectomy Laparoscopy Lymph Node Excision Neck Neoplasms Operative Surgical Procedures Ovariectomy Pelvis Radiography Salpingectomy Sentinel Lymph Node Uterus X-Ray Computed Tomography
The present study was conducted in accordance with the Declaration of Helsinki and approved by Ethics Committee of Nara Medical University (Approval no. 3048). Written informed consent was obtained from all patients involved. Between January, 2009 to December, 2018, 274 patients with PTC underwent lobectomy or total thyroidectomy at Nara Medical University (Kashihara, Japan) with or without paratracheal or lateral cervical lymph node dissection as an initial treatment. Patients were excluded if they were lost to follow-up for >3 years, had a history of distant metastasis at the time of the initial diagnosis, and had not undergone complete resection.
Publication 2023
Diagnosis Ethics Committees Lymph Node Excision Neck Neoplasm Metastasis Patients Thyroidectomy
The modified lithotomy position was taken, and all patients adopted the five trocar position with a pneumoperitoneum of 15 mmHg. One trocar was placed supraumbilical for the camera, while two trocars were placed on the right and left quadrant, respectively. After careful exploration, the patient was placed in the Trendelenburg position. The standard surgical technique was performed both in NOSES group and LAP group including separation and high ligation of the inferior mesenteric vessel, mobilization of the bowel, and dissection of the lymph nodes and and division of the distal rectum. Then the specimen extraction approach was different in two group. After the operation, both groups of patients will have 2 drainage tubes in the pelvic cavity, which are usually removed 5–7 days after the operation.
For LAP group, an auxiliary abdominal incision 6–8 cm in length was made for specimen extraction. Then, the anastomosis was performed by a double-stapling technique under the direct visual observation.
For NOSES group, after mobilization of the rectum and left colon, the distal rectum was transected below the tumor with a linear stapler. An incision was generated below the staple line of the rectal stump and a sterile plastic sleeve was placed into the abdominal cavity through the anus and rectal stump. Next, a long Babcock grasper was brought through the anus, and the specimen was extracted through the plastic sleeve (Figure 2A). Then, an anvil head attached to circular stapling device was inserted into the abdominal cavity, and a longitudinal incision approximately 2 cm was made on proximal colon wall to insert the anvil head (Figure 2B). Subsequently, the proximal colon was transected in close proximity to the upper pole of the incision using a linear stapler. Next, the rectum stump was transected with a linear stapling device. Finally, end-to-end colorectal anastomosis was performed with the use of a circular stapling device (Figure 2C). After the procedure, there is no auxiliary incision in the abdomen (Figure 2D).
Full text: Click here
Publication 2023
Abdomen Abdominal Cavity Amputation Stumps Anus Blood Vessel Colon Drainage Head Intestines Ligation Lymph Node Excision Medical Devices Mesentery Neoplasms Nose Patients Pelvis Pneumoperitoneum Rectum Sterility, Reproductive Surgery, Day Surgical Anastomoses Trocar

Top products related to «Lymph Node Excision»

Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Sourced in United States
The da Vinci Si Surgical System is a robotic-assisted surgical device designed for minimally invasive surgery. It is composed of a console where the surgeon sits and controls the robotic arms, and a patient-side cart with four robotic arms that hold the surgical instruments. The system allows the surgeon to perform complex surgical procedures with enhanced precision, flexibility, and control.
Sourced in United States, Austria, Japan, Belgium, New Zealand, United Kingdom, France
R is a free, open-source software environment for statistical computing and graphics. It provides a wide variety of statistical and graphical techniques, including linear and nonlinear modeling, classical statistical tests, time-series analysis, classification, clustering, and others.
Sourced in United States
The da Vinci Surgical System is a robotic-assisted surgical device designed for minimally invasive procedures. It consists of a surgeon's console, a patient-side cart with four robotic arms, and a high-definition 3D vision system. The system allows the surgeon to perform complex surgical maneuvers with enhanced dexterity, precision, and control.
Sourced in United States, Japan, United Kingdom, Austria, Germany, Czechia, Belgium, Denmark, Canada
SPSS version 22.0 is a statistical software package developed by IBM. It is designed to analyze and manipulate data for research and business purposes. The software provides a range of statistical analysis tools and techniques, including regression analysis, hypothesis testing, and data visualization.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States
The da Vinci Xi Surgical System is a robotic surgical platform designed to assist surgeons in performing a variety of minimally invasive surgical procedures. The system consists of a surgeon's console, a patient-side cart with four robotic arms, and a vision system. The system enables the surgeon to operate with enhanced precision, flexibility, and control through smaller incisions than traditional open surgical procedures.
Sourced in United States, United Kingdom, Germany, Japan, Belgium, Austria, China, Denmark, Spain
SPSS 22.0 is a statistical software package developed by IBM. It is designed to analyze and manipulate data, providing users with a range of statistical tools and techniques for various applications, including market research, survey data analysis, and social science research.
Sourced in United States, Switzerland
The da Vinci Xi system is a surgical robot designed for use in minimally invasive procedures. It features a console, patient-side cart, and camera and instrument arms. The system allows the surgeon to control the instruments and camera from the console, providing greater precision and control during the procedure.
Sourced in United States
The da Vinci System is a surgical robot designed for minimally invasive surgery. It consists of a surgeon's console, a patient-side cart with four interactive robotic arms, a high-definition 3D vision system, and specialized surgical instruments. The system allows the surgeon to perform complex surgical procedures with enhanced precision, flexibility, and control.

More about "Lymph Node Excision"

Lymph Node Removal, Lymphadenectomy, Lymph Node Dissection, Nodal Excision, Nodal Dissection, Lymphatic Surgery, Lymph Node Biopsy, Lymph Node Sampling, Lymph Node Aspiration, Lymph Node Aspiration Cytology, Lymph Node Aspiration Biopsy, Lymph Node Aspiration FNA, Lymph Node FNA, Lymph Node Puncture, Lymph Node Needle Aspiration, Lymph Node Needle Biopsy, Lymph Node Needle Aspiration Biopsy, Lymph Node Core Biopsy, Lymph Node Surgical Biopsy, Lymph Node Resection, Lymph Node Ablation, Lymph Node Extirpation, Lymph Node Debulking, Lymph Node Debulking Surgery, Lymph Node Excision Surgery, Lymph Node Excision Procedure, Lymph Node Removal Surgery, Lymph Node Removal Procedure, Lymph Node Harvesting, Lymph Node Harvesting Surgery, Lymph Node Harvesting Procedure, Lymph Node Harvesting Technique, Sentinel Lymph Node Biopsy, Sentinel Node Biopsy, Sentinel Node Mapping, Sentinel Node Dissection, Sentinel Node Excision, Lymphatic Mapping, Lymphatic System Evaluation, Lymphatic System Assessment, Lymphatic System Staging, Lymphatic System Imaging, Lymphatic System Mapping, Lymphatic System Intervention, Lymphatic System Procedure, Lymphatic System Surgery, Lymphatic System Diagnostics, Lymphatic System Therapeutics, Lymphatic System Management, Lymphatic System Care, Lymphatic System Treatment, Lymphatic System Evaluation and Management, Lymphatic System Diagnosis and Treatment, Lymphatic System Examination and Intervention, Lymphatic System Assessment and Procedure, Lymphatic System Imaging and Surgery, Lymphatic System Mapping and Biopsy, Lymphatic System Evaluation and Therapy, Lymphatic System Staging and Excision, Lymphatic System Diagnostics and Resection, Lymphatic System Intervention and Harvesting, Lymphatic System Procedure and Ablation, Lymphatic System Surgery and Debulking, Lymphatic System Care and Extirpation, Lymphatic System Treatment and Puncture, Lymphatic System Evaluation and Aspiration, Lymphatic System Diagnosis and Harvesting, Lymphatic System Assessment and Removal, Lymphatic System Imaging and Excision, Lymphatic System Mapping and Dissection, Lymphatic System Intervention and Biopsy, Lymphatic System Procedure and Sampling, Lymphatic System Surgery and FNA, Lymphatic System Care and Cytology, Lymphatic System Treatment and Needle Aspiration, Lymphatic System Evaluation and Needle Biopsy.
The insights from SAS version 9.4, Da Vinci Si Surgical System, R software, Da Vinci Surgical System, SPSS version 22.0, FBS, Da Vinci Xi Surgical System, SPSS 22.0, Da Vinci Xi system, Da Vinci system can be leveraged to enhance the reproducibility, accuracy, and overall research outcomes for Lymph Node Excision procedures.